Edition:
United Kingdom

Biotechnology & Medical Research

Dupixent Shows Positive Topline Results In Two Phase 3 Trials Of Patients

Oct 16 (Reuters) - Regeneron Pharmaceuticals Inc ::DUPIXENT® (DUPILUMAB) SHOWED POSITIVE TOPLINE RESULTS IN TWO PHASE 3 TRIALS OF PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS.DUPIXENT® (DUPILUMAB) SHOWED POSITIVE TOPLINE RESULTS IN TWO PHASE 3 TRIALS OF PATIENTS WITH CHRONIC RHINOSINUSITIS...

5:59am BST

Orgenesis Q3 Loss Per Share $0.35

Oct 15 (Reuters) - Orgenesis Inc ::ORGENESIS REPORTS 143% INCREASE IN REVENUE AND 316% INCREASE IN GROSS PROFIT FOR THE THIRD QUARTER OF FISCAL 2018.Q3 LOSS PER SHARE $0.35.Q3 REVENUE ROSE 143 PERCENT TO $6.2 MILLION.QUARTER ENDED WITH $16.7 MILLION OF CASH AND APPROXIMATELY $30 MILLION OF...

Monday, 15 Oct 2018

Vital Therapies Provides Strategic Update

Oct 11 (Reuters) - Vital Therapies Inc ::VITAL THERAPIES PROVIDES STRATEGIC UPDATE.VITAL THERAPIES INC - COMPANY UNDERWENT A REDUCTION IN FORCE OF APPROXIMATELY 80% OF ITS WORKFORCE.VITAL THERAPIES - HAS RETAINED LADENBURG THALMANN & CO INC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST IN REVIEW OF...

Thursday, 11 Oct 2018

MEI Pharma And Beigene Announce Clinical Collaboration

Oct 11 (Reuters) - Beigene Ltd ::MEI PHARMA AND BEIGENE ANNOUNCE CLINICAL COLLABORATION TO EVALUATE ME-401 IN COMBINATION WITH ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES.MEI PHARMA INC - STUDY COSTS WILL BE SHARED EQUALLY BY PARTIES, AND MEI WILL SUPPLY ME-401 AND BEIGENE WILL SUPPLY...

Thursday, 11 Oct 2018

Expansion & New Markets

Markets

  • Sectors
  • Europe
  • U.S.
  • Asia

Sector Summary

Upcoming Events

No related earnings announcements are currently scheduled within the next 7 days.